Endocannabinoids

European Journal of Pharmacology

Volumn 359, Issue 1, 1998, Pages 1-18

  Mechoulam, Raphael ^a   Fride, Ester ^a   Di Marzo, Vincenzo ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b CNR   (Italy)

Author keywords

2 Arachidonoyl glycerol; Anandamide; Cannabis; Tetrahydrocannabinol

Indexed keywords

ANANDAMIDE; ANESTHETIC AGENT; CALCIUM ION; CANNABINOID; CANNABINOID RECEPTOR; DEXANABINOL; DRONABINOL; ENDOTHELIUM DERIVED RELAXING FACTOR; FATTY ACID; GLYCEROL DERIVATIVE; NABILONE; RIMONABANT; SEROTONIN 3 ANTAGONIST; STEROID;

ANALGESIA; ASTROCYTE; BRADYCARDIA; CALCIUM TRANSPORT; COVALENT BOND; DIFFUSION; DRUG HYDROLYSIS; DRUG ISOLATION; DRUG MECHANISM; DRUG RELEASE; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERANCE; DRUG TRANSPORT; INTRATHECAL DRUG ADMINISTRATION; LEARNING; LIPID SOLUBILITY; MEMBRANE FLUIDITY; MEMBRANE STRUCTURE; MEMORY; NAUSEA; NIDATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STEREOCHEMISTRY; STILLBIRTH; STRUCTURE ACTIVITY RELATION;

ANIMALS; ARACHIDONIC ACIDS; CANNABINOIDS; CANNABIS; ENDOCANNABINOIDS; GLYCERIDES; HUMANS; MICE; POLYUNSATURATED ALKAMIDES; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROCANNABINOL;

EID: 0032538527     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00649-9     Document Type: Review

References (173)

1. Abadji V., Lin S., Taha G., Griffin G., Stevenson L.A., Pertwee R.G., Makriyannis A. (R)-Methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J. Med. Chem. 37:1994;1889-1893.
2. Abrahamov A., Abrahamov A., Mechoulam R. An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci. 56:1995;2097-2102.
3. Adams I.B., Ryan W., Singer M., Razdan R.K., Compton D.R., Martin B.R. Pharmacological and behavioral evaluation of alkylated anandamide analogs. Life Sci. 56:1995;2041-2048.
4. Adams I.B., Compton D.R., Martin B.R. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J. Pharmacol. Exp. Ther. 284:1998;1209-1217.
5. 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol. Rev. 38:1986;21-43.
6. Allen A.C., Gammon C.M., Ousley A.H., McCarth K.D., Morell P. Bradykinin stimulates arachidonic acid release through the sequential actions of an sn-1-diacylglycerol lipase and a monoacylglycerol lipase. J. Neurochem. 58:1992;1130-1139.
7. Arreaza G., Devane W.A., Omeir R.L., Sajnani G., Kunz J., Cravatt B.F., Deutsch D.G. The cloned rat hydrolytic enzyme responsible for the breakdown of anandamide also catalyzes its formation via the condensation of arachidonic acid and ethanolamine. Neurosci. Lett. 234:1997;59-62.
8. Axelrod J., Felder C.C. Cannabinoid receptors and their endogenous agonist, anandamide. Neurochem. Res. 23:1998;575-581.
9. Barg J., Fride E., Hanuš L., Levy R., Matus-Leibovitch N., Heldman E., Bayewitch M., Mechoulam R., Vogel Z. Cannabimimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. Eur. J. Pharmacol. 287:1995;145-152.
10. Beltramo M., Stella A., Calignano S.Y., Lin A., Makryannis A., Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science. 277:1997;1094-1097.
11. Ben-Shabat S., Fride E., Sheshkin T., Tamiri T., Rhee M.-H., Vogel Z., Bisogno T., De Petrocellis L., Di Marzo V., Mechoulam R. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur. J. Pharmacol. 353:1998;23-31.
12. Berdyshev E.V., Boichot E., Germain N., Allain N., Anger J.P., Lagente V. Influence of fatty acid ethanolamides and delta9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. Eur. J. Pharmacol. 330:1997;231-240.
13. Bisogno T., Maurelli S., Melck D., De Petrocellis L., Di Marzo V. Biosynthesis, uptake and degradation of anandamide and palmitoylethanolamide in leukocytes. J. Biol. Chem. 272:1997;3315-3323.
14. Bisogno T., Sepe N., Melck D., Maurelli S., De-Petrocellis L., Di Marzo V. Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem. J. 322:1997;671-677.
15. Bisogno T., Ventriglia M., Milone A., Mosca M., Cimino G., Di-Marzo V. Occurrence and metabolism of anandamide and related acyl-ethanolamides in ovaries of the sea urchin Paracentrotus lividus. Biochim. Biophys. Acta. 1345:1997;338-348.
16. Bisogno T., Katayama K., Melck D., Ueda N., De Petrocellis L., Yamamoto S., Di Marzo V. Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cell. Implications for cell proliferation and differentiation. Eur. J. Biochem. 254:1998;634-642.
17. Boger D.L., Patterson J.E., Guan X., Cravatt B.F., Lerner R.A., Gilula N.B. Chemical requirements for inhibition of gap junction communication by the biologicaly active lipid oleamide. Proc. Natl. Acad. Sci. USA. 95:1998;4810-4815.
18. Bornheim L.M., Kim K.Y., Chen B., Correia M.A. The effect of cannabidiol on mouse hepatic microsomal cytochrome P450-dependent anandamide metabolism. Biochem. Biophys. Res. Commun. 197:1993;740-746.
19. Cadas H., Gaillet S., Beltramo M., Venance L., Piomelli D. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J. Neurosci. 16:1996;3934-3942.
20. Cadas H., di Tomaso E., Piomelli D. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J. Neurosci. 17:1997;1226-1242.
21. Cadogan A.K., Alexander S.P., Boyd E.A., Kendall D.A. Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. J. Neurochem. 69:1997;1131-1137.
22. Calignano A., La-Rana G., Beltramo M., Makriyannis A., Piomelli D. Potentiation of anandamide hypotension by the transport inhibitor, AM404. Eur. J. Pharmacol. 337:1997;R1-R2.
23. Calignano A., La Rana G., Makryannis A., Lin S.Y., Beltramo M., Piomelli D. Inhibition of intestinal motility by anandamide, an endogenous cannabinoid. Eur. J. Pharmacol. 340:1997;R7-R8.
24. Chakrabarti A., Ekuta J.E., Onaivi E.S. Neurobehavioral effects of anandamide and cannabinoid receptor gene expression in mice. Brain. Res. Bull. 45:1998;67-74.
25. Compton D.R., Martin B.R. The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity. J. Pharmacol. Exp. Ther. 283:1997;1138-1143.
26. Cravatt B.F., Prospero-Carcia O., Siuzdak G., Gilula N.B., Henriksen S.J., Boger D.L., Lerner R.A. Chemical characterization of a family of brain lipids that induce sleep. Science. 268:1995;1506-1509.
27. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 384:1996;83-87.
28. Das S.K., Paria B.C., Chakraborty I., Dey S.K. Cannabinoid ligand-receptor signaling in the mouse uterus. Proc. Natl. Acad. Sci. USA. 92:1995;4332-4336.
29. De Petrocellis L., Melck D., Palmisano A., Bisogno T., Laezza C., Bifulco M., Di Marzo V. The endogenous cannabinoid anandamide inhibits human breast cancer cel proliferation. Proc. Natl. Acad. Sci. USA. 95:1998;8375-8380.
30. Derocq J.M., Sequi M., Marhand J., Lefur G., Casellas P. Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEBS Lett. 369:1995;177-182.
31. Deutsch D.G., Chin S.A. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol. 46:1993;791-796.
32. Deutsch D.G., Goligorsky M.S., Schmid P.C., Krebsbach R.J., Schmid H.H.O., Das S.K., Dey S.K., Arreaza G., Thorup C., Stefano G., Moore L.C. Production and physiological actions of anandamide in the vasculature of the rat kidney. J. Clin. Invest. 100:1997;1538-1546.
33. Devane W.A., Dysarz F.A.I.I.I., Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:1988;605-613.
34. Devane W.A., Breuer A., Sheskin T., Järbe T.U.C., Eisen M.S., Mechoulam R. A novel probe for the cannabinoid receptor. J. Med. Chem. 35:1992;2065-2069.
35. Devane W.A., Hanuš L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
36. Dewey W.L. Cannabinoid pharmacology. Pharmacol. Rev. 38:1986;151-178.
37. Dewey, W.L., Martin, B.R., May, E.L., 1984. Cannabinoid stereoisomers: pharmacological effects. In: Smith, D.F. (Ed.), Handbook of Stereoisomers: Drugs in Psychpharmacology. CRC Press, Boca Raton, FL, pp. 317-326.
38. Di Marzo V. Arachidonic acid and eicosanoids as targets and effectors in second messenger interactions. Prostaglandins, Leukot., Essent. Fatty Acids. 53:1995;239-254.
39. Di Marzo V. Endocannabinoids and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim. Biophys. Acta. 1392:1998;153-175.
40. Di Marzo, V., Deutsch, D.G., 1998. Biochemistry of the endogenous ligands of cannabinoid receptors. Semin. Neurosci., in press.
41. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.-C., Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 372:1994;686-691.
42. Di Marzo V., De Petrocellis L., Sepe N., Buono A. Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem. J. 316:1996;977-984.
43. Di Marzo V., De Petrocellis L., Sugiura T., Waku K. Potential biosynthetic connections between the two cannabimimetic eicosanoids, anandamide and 2-arachidonoyl-glycerol, in mouse neuroblastoma cells. Biochem. Biophys. Res. Commun. 227:1996;281-288.
44. Di Marzo V., Bisogno T., Sugiura T., Melck D., De-Petrocellis L. The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. Biochem. J. 331:1998;15-19.
45. Di Tomaso E., Beltramo M., Piomelli D. Brain cannabinoids in chocolate. Nature. 382:1997;677-678.
46. Edgemond W.S., Hillard C.J., Falck J.R., Kearn C.S., Campbell W.B. Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonoylethanolamide (anandamide): their affinities for cannabinoid receptors and pathways of inactivation. Mol. Pharmacol. 54:1998;180-188.
47. Ellis E.F., Moore S.F., Willoughby K.A. Anandamide and delta 9-THC dilation of cerebral arterioles is blocked by indomethacin. Am. J. Physiol. 269:1995;H1859-H1864.
48. Facci L., Dal Toso R., Romanello S., Buriani A., Skaper S.D., Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. USA. 92:1995;3376-3380.
49. Fan P. Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J. Neurophysiol. 73:1995;907-910.
50. Felder C.C., Glass M. Cannabinoid receptors and their endogenous agonists. Annu. Rev. Pharmacol. Toxicol. 38:1998;179-200.
51. Felder C.C., Briley E.M., Axelrod J., Simpson J.T., Mackie K., Devane W.A. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc. Natl. Acad. Sci. USA. 90:1993;7656-7660.
52. Felder C.C., Nielsen A., Briley E.M., Palkovits M., Priller J., Axelrod J., Nguyen D.N., Richardson J.M., Riggin R.M., Koppel G.A., Paul S.M., Becker G.W. Isolation and measurement of the endogenous cannabinoid receptor agonist, anadamide, in the brain and peripheral tissues of human and rat. FEBS Lett. 393:1996;231-235.
53. Felder C.C., Joyce K.E., Briley E.M., Glass M., Mackie K.P., Fahey K.J., Cullinan G.J., Hunden D.C., Johnson D.W., Chaney M.O., Koppel G.A., Brownstein M. LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J. Pharmacol. Exp. Ther. 284:1998;291-297.
54. Fernandez-Ruiz J.J., Munoz R.M., Romero J., Villanua M.A., Makriyannis A., Ramos J.A. Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics. Biochem. Pharmacol. 53:1997;1919-1927.
55. Fontana A., Di Marzo V., Cadas H., Piomelli D. Analysis of anandamide, an endogenous cannabinoid substance, and of other natural N-acylethanolamines. Prostaglandins, Leukot., Essent. Fatty Acids. 53:1995;301-308.
56. Fride E. Anandamides: tolerance and cross-tolerance to Delta(9)-tetrahydrocannabinol. Brain Res. 697:1995;83-90.
57. Fride E., Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur. J. Pharmacol. 231:1993;313-314.
58. Fride E., Mechoulam R. Developmental aspects of anandamide: ontogeny of response and prenatal exposure. Psychoneuroendocrinology. 21:1996;157-172.
59. 9-tetrahydrocannabinol in mice. Dev. Brain Res. 95:1996;131-134.
60. Fride, E., Hanuš, L., Mechoulam, R., 1994. Discovery of the anandamides, a family of endogenous ligands for the cannabinoid receptor. In: Zor, U. (Ed.), Lipid Mediators in Health and Disease. Freund Publishing, London, pp. 1-10.
61. 9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 272:1995;699-707.
62. Fride, E., Bisogno, T., Di Marzo, V., Bayewitch, M., Vogel, Z., Mechoulam, R., 1997. Anadamide: Modulator of the effects of oleamide (a sleep factor) and chocolate? Society for Neuroscience 27th Annual Meeting, New Orleans, LA, p. 1230.
63. Fride, E., Ben-Shabat, S., Mechoulam, R., 1998. Pharmacology of anandamide: Interaction with serotonin systems? 1998 Symposium on the Cannabinoids, Burlington, VT, International Cannabinoid Research Society.
64. Gaoni Y., Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86:1964;1646.
65. Gerard C.M., Mollereau C., Vassart G., Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem. J. 279:1991;129-134.
66. Gill E.W. The effects of cannabinoids and other CNS depressants on cell membrane models. Ann. N.Y. Acad. Sci. 281:1976;151-161.
67. Gill, E.W., Lawrence, D.K., 1976. The physiochemical mode of action of tetrahydrocannabinol on cell membranes. In: Braude, M.C., Szara, S. (Eds.), Pharmacology of Marihuana, pp. 147-155. Raven Press, New York, NY.
68. Giuffrida A., Piomelli D. Isotope dilution GC/MS determination of anandamide and other fatty acylethanolamides in rat blood plasma. FEBS Lett. 422:1998;373-376.
69. Glaser R., Adin I., Mechoulam R., Hanuš L. 2-Methyl and 4-methyl-delta-8-terahydrocannabinol: correlation of spatial distinction with cannabinoid receptor binding. Heterocycles. 39:1995;867-877.
70. Glass M., Felder C.C. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptor augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J. Neurosci. 17:1997;5327-5333.
71. Goparaju S.K., Ueda N., Yamagucchi H., Yamamoto S. Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett. 422:1998;69-73.
72. Greenshaw A.J. Behavioural pharmacology of 5-HT3 receptor antagonists: a critical update on therapeutic potential. Trends Pharmacol. Sci. 14:1993;265-270.
73. Greenshaw A.J., Silverstone P.H. The non-antiemetic uses of serotonin 5-HT3 receptor antagonists. Drugs. 53:1997;20-39.
74. Gueudet C., Santucci V., Rinaldi-Carmona M., Soubrie P., Le-Fur G. The CB1 cannabinoid receptor antagonist SR 141716A affects A9 dopamine neuronal activity in the rat. NeuroReport. 6:1995;1421-1425.
75. Hampson A.J., Hill W.A., Zan-Phillips M., Makriyannis A., Leung E., Eglen R.M., Bornheim L.M. Anandamide hydroxylation by brain lipoxygenase: metabolite structures and potencies at the cannabinoid receptor. Biochim. Biophys. Acta. 1259:1995;173-179.
76. Hampson A.J., Bornheim L.M., Scanziani M., Yost C.S., Gray A.T., Hansen B.M., Leonoudakis D.J., Bickler P.E. Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. J. Neurochem. 70:1998;671-676.
77. Hansen H.S., Lauritzen L., Strand A.M., Vinggaard A.M., Frandsen A., Schousboe A. Characterization of glutamate-induced formation of N-acylphosphatidylethanolamine and N-acylethanolamine in cultured neocortical neurons. J. Neurochem. 69:1997;753-761.
78. Hanuš L., Gopher A., Almog S., Mechoulam R. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J. Med. Chem. 36:1993;3032-3034.
79. Hasegawa-Sassaki H. Early changes in inositol lipids and their metabolites induced by platelet-derived growth factor in quiescent Swiss mouse 3T3 cells. Biochem. J. 232:1985;99-109.
80. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA. 87:1990;1932-1936.
81. Hillard C.J., Edgemond W.S., Jarrahian A., Campbell W.B. Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J. Neurochem. 69:1997;631-638.
82. Howlett A.C. Cannabinoid inhibition of adenylate cyclase: relative activity of constituents and metabolites of marihuana. Neuropharmacology. 26:1987;507-512.
83. Howlett, A.C., 1995. Cannabinoid compounds and signal transduction mechanisms. In: Pertwee, R. (Ed.), Cannabinoid Receptors. Academic Press, London, pp. 167-204.
84. Howlett A.C. Pharmacology of cannabinoid receptors. Annu. Rev. Pharmacol. Toxicol. 35:1995;607-634.
85. Howlett A.C., Fleming R.M. Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol. Pharmacol. 26:1984;532-538.
86. Howlett A.C., Qualy J.M., Khachatrian L.L. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol. Pharmacol. 29:1986;307-313.
87. Howlett A.C., Champion T.M., Wilken G.H., Mechoulam R. Stereochemical effects of 11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor. Neuropharmacology. 29:1990;161-165.
88. Jarrahian A., Hillard C.J. Arachidonylethanolamide (anandamide) binds with low affinity to dihydropyridine binding sites in brain membranes. Prostaglandins, Leukot., Essent. Fatty Acids. 57:1997;551-554.
89. Katayama K., Ueda N., Kurahashi Y., Suzuki H., Yamamoto S., Kato I. Distribution of anandamide amidohydrolase in rat tissues with special reference to small intestine. Biochim. Biophys. Acta. 1347:1997;212-218.
90. Kempe K., Hsu F.F., Bohrer A., Turk J. Isotope dilution mass spectrometric measurements indicate that arachidonylethanolamide, the proposed endogenous ligand of the cannabinoid receptor, accumulates in rat brain tissue post mortem but is contained at low levels in or is absent from fresh tissue. J. Biol. Chem. 271:1996;17287-17295.
91. Khan W.A., Blobe G.C., Hannun Y.A. Arachidonic acid and free fatty acids as second messengers and the role of protein kinase C. Cell Signal. 7:1995;171-184.
92. Kimura I., Ohta T., Watanabe K., Yoshimura H., Yamamoto I. Anandamide, an endogenous cannabinoid receptor ligand, also interacts with 5-hydroxytryptamine (5-HT) receptor. Biol. Pharm. Bull. 21:1998;224-226.
93. Koga D., Santa T., Hagiwara K., Imai K., Takizawa H., Nagano T., Hirobe M., Ogawa M., Sato T., Inoue K.et al. High performance liquid chromatography and fluorometric detection of arachidonoylethanolamide (anandamide) and its analogues, derivatized with 4-(N-chloroformylmethyl-N-methyl)amino-7-N,N-dimethylaminosulp honyl-2,1, 3-benzoxadiazole (DBD-COCl). Biomed. Chromatogr. 9:1995;56-57.
94. Koga D., Santa T., Fukushima T., Homma H., Imai K. Liquid chromatographic-atmospheric pressure chemical ionization mass spectrometric determination of anandamide and its analogs in rat brain and peripheral tissues. J. Chromatogr. B. Biomed. Appl. 690:1997;7-13.
95. Kurahashi Y., Ueda N., Suzuki H., Suzuki M., Yamamoto S. Reversible hydrolysis and synthesis of anandamide demonstrated by recombinant rat fatty acid amide hydrolase. Biochem. Biophys. Res. Commun. 237:1997;512-515.
96. Kuwae T., Schmid P.C., Schmid H.H.O. Alterations of fatty acyl turnover in macrophage glycerolipids induced by stimulation. Evidence for enhanced recycling of arachidonic acid. Biochim. Biophys. Acta. 1344:1997;74-86.
97. Lake K.D., Compton D.R., Varga K., Martin B.R., Kunos G. Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J. Pharmacol. Exp. Ther. 281:1997;1030-1037.
98. Langstein J., Hofstadter F., Schwarz H. Cis-9,10-octadecenoamide, an endogenous sleep-inducing CNS compound, inhibits lymphocyte proliferation. Res. Immunol. 147:1996;389-396.
99. Lee, M., Yang, K.H., Kaminski, N.E., 1995. Effect of putative cannabinoid ligands, anandamide and 2-arachidonyl-glycerol, on immune function in B6C3F1 mouse splenocytes. J. Pharamcol. Exp. Ther. 529-536.
100. Lerner R.A. A hypothesis about the endogenous analogue of general anesthesia. Proc. Natl. Acad. Sci. USA. 94:1997;13375-13377.
101. Mackie K., Devane W.A., Hille B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol. 44:1993;498-503.
102. Makriyannis, A., 1995. The role of cell membranes in cannabinoid activity in cannabioid receptors. In: Pertwee, R.G. (Ed.), Cannabinoid Receptors. Academic Press, London, pp. 87-115.
103. Mallet P.E., Beninger R.J. The enogenous cannabinoid receptor agonist anandamide impairs memory in rats. Behav. Pharmacol. 7:1996;276-284.
104. Martin B.R. Cellular effects of cannabinoids. Pharmacol. Rev. 38:1986;45-74.
105. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
106. Maurelli S., Bisogno T., De Petrocellis L., Di-Luccia A., Marino G., Di Marzo V. Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma 'anandamide amidohydrolase'. FEBS Lett. 377:1995;82-86.
107. Mechoulam, R., 1973. Cannabinoid chemistry. In: Mechoulam, R. (Ed.), Marijuana. Chemistry, Metabolism, Pharmacology and Clinical Effects. Academic Press, New York, NY, pp. 1-99.
108. Mechoulam, R., 1986 (Ed.), Cannabinoids as Therapeutic Agents. CRC Press, Boca Raton, FL.
109. Mechoulam, R., Fride, E., 1995. The unpaved road to the endogenous brain cannabinoid ligands, the anandamides. In: Pertwee, R.G. (Ed.), Cannabinoid Receptors. Academic Press, London, pp. 233-258.
110. Mechoulam R., Shvo Y. The structure of cannabidiol. Tetrahedron. 19:1963;2073-2978.
111. Mechoulam, R., Devane, W.A., Glaser, R., 1992. Cannabinoid geometry and biological activity. In: Murphy, L., Bartke, A. (Eds.), Marijuana/cannabinoids: neurobiology and neurophysiology. CRC Press, Boca Raton, FL, pp. 1-33.
112. Mechoulam R., Ben-Shabat S., Hanuš L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., Compton D.R., Pertwee R.G., Griffin G., Bayewitch M., Barg J., Vogel Z. Identification of an endogenous 2-mono-glyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50:1995;83-90.
113. Mechoulam R., Fride E., Hanuš L., Sheshkin T., Bisogno T., Di Marzo V., Bayewitch M., Vogel Z. Anandamide may mediate sleep induction. Nature. 389:1997;25-26.
114. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
115. Ouyang Y.L., Hwang S.G., Han S.H., Kaminski N.E. Suppression of interleukin-2 by the putative endogenous cannabinoid 2-arachidonyl-glycerol is mediated through down-regulation of the nuclear factor of activated T cells. Mol. Pharmacol. 53:1998;676-683.
116. Pate D.W., Jarvinen K., Urtti A., Jarho P., Jarvinen T. Ophtalmic arachidonylethanolamide decreasse intraocular pressure in normotensive rabbits. Curr. Eye Res. 14:1995;791-797.
117. Paton W.D. Pharmacology of marijuana. Annu. Rev. Pharmacol. 15:1975;191-220.
118. Paton, W.D.M., Pertwee, R.G., 1973. The pharmacology of cannabis in animals. In: Mechoulam, R. (Ed.), Marijuana: Chemistry, Pharmacology, Metabolism and Clinical Effects. Academic Press, New York, NY, pp. 191-285.
119. Pertwee, 1995 (Ed.), Cannabinoid receptors, Academic Press, London.
120. Pertwee R., Griffin G., Hanuš L., Mechoulam R. Effects of two endogenous fatty acid ethanolamides on mouse vasa deferentia. Eur. J. Pharmacol. 259:1994;115-120.
121. Pinto J.C., Potie F., Rice K.C., Boring D., Johnson M.R., Evans D.M., Wilken G.H., Cantrell C.H., Howlett A.C. Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid. Mol. Pharmacol. 46:1994;516-522.
122. Plane F., Holland M., Waldron G.J., Garland C.J., Boyle J.P. Evidence that anandamide and EDHF act via different mechanisms in rat isolated mesenteric arteries. Br. J. Pharmacol. 121:1997;1509-1511.
123. Pratt P.F., Hillard C.J., Edgemond W.S., Campbell W.B. N-arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor. Am. J. Physiol. 274:1998;H375-H381.
124. Priller J., Briley E.M., Mansouri J., Devane W.A., Mackie K., Felder C.C. Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors. Mol. Pharmacol. 48:1995;288-292.
125. Randall M.D., Kendall D.A. Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation. Eur. J. Pharmacol. 335:1997;205-209.
126. Randall M.D., Kendall D.A. Anandamide and endothelium-derived hyperpolarizing factor act via a common vasorelaxant mechanism in rat mesentery. Eur. J. Pharmacol. 346:1998;51-53.
127. Randall M.D., Kendall D.A. Endocannabinoids: a new class of vasoactive substances. Trends Pharmacol. Sci. 19:1998;55-58.
128. Randall M.D., Alexander S.P.H., Bennett T., Boyd E.A., Fry J.R., Gardiner S.M., Kemp P.A., McColloch A.I., Kendall D.A. An endogenous cannabinoid as an endothelium derived vasorelaxant. Biochem. Biophys. Res. Commun. 229:1996;114.
129. Razdan R.K. Structure-activity relationships in cannabinoids. Pharmacol. Rev. 38:1986;75-149.
130. Richardson J.D., Aanonsen L., Hargreaves K.M. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J. Neurosci. 18:1998;451-457.
131. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., Caput D., Ferrara P., Soubrie P., Breliere J.C., Le Fur G. SR14171A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
132. Ryan W.J., Banner W.K., Wiley J.L., Martin B.R., Razdan R.K. Potent anandamide analogs: the effect of changing the length and branching of the end pentyl chain. J. Med. Chem. 40:1997;3617-3625.
133. Schmid H.H.O., Schmid P.C., Natarajan V. N-acylated glycerophospholipids and their derivatives. Prog. Lipid. Res. 29:1990;1-43.
134. Schmid P.C., Krebsbach R.J., Perry S.R., Dettmer T.M., Maasson J.L., Schmid H.H.O. Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. FEBS Lett. 375:1995;117-120.
135. Schmid H.H.O., Schmid P.C., Natarajan V. The N-acylation-phosphodiesterase pathway and cell signalling. Chem. Phys. Lipids. 80:1996;133-142.
136. Schmid P.C., Paria B.C., Krebsbach R.J., Schmid H.H.O., Dey S.K. Changes in anandamide levels in mouse uterus are associated with uterine receptivity for embryo implantation. Proc. Natl. Acad. Sci. USA. 94:1997;4188-4192.
137. Schuel H., Goldstein E., Mechoulam R., Zimmerman A.M., Zimmerman S. Anandamide (arachidonylethanolamide), a brain cannabinoid receptor agonist, reduces sperm fertilizing capacity in sea urchins by inhibiting the acrosome reaction. Proc. Natl. Acad. Sci. USA. 91:1994;7678-7682.
138. Schwarz H., Blanco F.J., Lotz M. Anadamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J. Neuroimmunol. 55:1994;107-115.
139. Seltzman H.H., Fleming D.N., Thomas B.F., Gilliam A.F., McCallion D.S., Pertwee R.G., Compton D.R., Martin B.R. Synthesis and pharmacological comparison of dimethylheptyl and pentyl analogs of anandamide. J. Med. Chem. 40:1997;3626-3634.
140. Sepe N., De Petrocellis L., Montanaro F., Cimino G., Di Marzo V. Bioactive long chain N-acylethanolamines in five species of edible bivalve molluscs. Possible implications for mollusc physiology and sea food industry. Biochim. Biophys. Acta. 1389:1998;101-111.
141. Shears, S.B., 1993. Regulation of the metabolism of 1,2-diacylglycerols and inositol phosphates that respond to receptor activation. In: Taylor, C.W. (Ed.), Intracellular messengers. Elsevier, Amsterdam, pp. 315-346.
142. Sheskin T., Hanuš L., Slager J., Vogel Z., Mechoulam R. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J. Med. Chem. 40:1997;659-667.
143. Souilhac J., Poncelet M., Rinaldi-Carmona M., Le Fur G., Soubrie P. Intrastriatal Injection of cannabinoid receptor agonists induced turning behavior in mice. Pharmacol. Biochem. Behav. 51:1995;3-7.
144. Stella N., Schweitzer P., Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 388:1997;773-778.
145. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., Waku K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215:1995;89-97.
146. Sugiura T., Kondo S., Sukagawa A., Tonegawa T., Nakane S., Yamashita A., Ishima Y., Waku K. Transacylase-mediated and phosphodiesterase-mediated synthesis of N-arachidonoylethanolamine, an endogenous cannabinoid-receptor ligand, in rat brain microsomes. Comparison with synthesis from free arachidonic acid and ethanolamine. Eur. J. Biochem. 240:1996;53-62.
147. Sugiura T., Kondo S., Sukagawa A., Tonegawa T., Nakane S., Yamashita A., Waku K. Enzymatic synthesis of anandamide, an endogenous cannabinoid receptor ligand, through N-acylphosphatidylethanolamine pathway in testis: involvement of Ca(2+)-dependent transacylase and phosphodiesterase activities. Biochem. Biophys. Res. Commun. 218:1996;113-117.
148. Sugiura T., Kodaka T., Nakane S., Kishimoto S., Kondo S., Waku K. Detection of an endogenous cannabimimetic molecule, 2-arachidonoylglycerol, and cannabinoid CB1 receptor mRNA in human vascular cells: is 2-arachidonoylglycerol a possible vasomodulator? Biochem. Biophys. Res. Commun. 243:1998;838-843.
149. Sulcova E., Mechoulam R., Fride E. Biphasic effects of anandamide. Pharmacol. Biochem. Behav. 59:1998;347-353.
150. 1H -NMR spectra of model membranes J. Pharm. Sci. 72:1983;458-461.
151. Terranova J.P., Mechaud J.C., Lefur G., Soubrie P. Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN 55212-2: reversal by SR141716A, a selective antagonist of CB1 cannabinoid receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 352:1995;576-579.
152. Thomas B.F., Adams I.B., Mascarella W., Martin B.R., Razdan R.K. Structure-activity analysis of anandamide analogs: relationship to a cannabinoid pharmacophore. J. Med. Chem. 39:1996;471-479.
153. Thomas E.A., Carson M.J., Neal M.J., Sutcliffe J.G. Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide. Proc. Natl. Acad. Sci. USA. 94:1997;14115-14119.
154. Thomas E.A., Cravatt B.F., Danielson P.E., Gilula N.B., Sutcliffe J.G. Fatty acid amide hydrolase, the degradative enzyme for anandamide and oleamide, has selective distribution in neurons within the rat central nervous system. J. Neurosci. Res. 50:1997;1047-1052.
155. Ueda H., Kobayashi T., Kishimoto M., Tsutsumi T., Okuyama H. A possible pathway of phosphoinositide metabolism through EDTA-insensitive phospholipase A1 followed by lysophosphoinositide-specific phospholipase C in rat brain. J. Neurochem. 61:1993;1874-1881.
156. Ueda N., Yamamoto K., Yamamoto S., Tokunaga T., Shirakawa E., Shinkai H., Ogawa M., Sato T., Kudo I., Inoue K.et al. Lipoxygenase-catalyzed oxygenation of arachidonylethanolamide, a cannabinoid receptor agonist. Biochim. Biophys. Acta. 1254:1995;127-134.
157. Varga K., Lake K., Martin B.R., Kunos G. Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur. J. Pharmacol. 278:1995;279-283.
158. Varga K., Wagner J.A., Bridgen T.D., Kunos G. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J. 12:1998;1035-1044.
159. Venance L., Piomelli D., Glowinski J., Giaume C. Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes. Nature. 376:1995;590-594.
160. Vogel Z., Barg J., Levy R., Saya D., Heldman E., Mechoulam R. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J. Neurochem. 61:1993;352-355.
161. Wagner J.A., Varga K., Ellis E.F., Rzigalinski B.A., Martin B.R., Kunos G. Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature. 390:1997;518-521.
162. Weidenfeld J., Feldman S., Mechoulam R. The effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinology. 59:1994;110-112.
163. 9-THC and CP 55,940 following intrathecal administration to mice: effects of Kappa1 antisense pretreatment. Drug and Alcohol Dependence. 45:1995;39-45.
164. 9-THC-induced interactions with dynorphinergic systems. Drug Alcohol Depend. 45:1997;39-45.
165. Welch S.P., Dunlow L.D., Patrick G.S., Razdan R.K. Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception. J. Pharmacol. Exp. Ther. 273:1995;1235-1244.
166. Wenger T., Fragkakis G., Giannikou P., Probonas K., Yiannikakis N. Effects of anandamide on gestation in pregnant rats. Life Sci. 60:1997;2361-2371.
167. Wenger T., Jamali K.A., Juaneda C., Leonardelli J., Tramu G. Arachidonyl ethanolamide (anandamide) activates the parvocellular part of hypothalamic paraventricular nucleus. Biochem. Biophys. Res. Commun. 237:1997;724-728.
168. Wiley J., Balster R., Martin B. Discriminative stimulus effects of anandamide in rats. Eur. J. Pharmacol. 276:1995;49-54.
169. Wiley J.L., Golden K.M., Ryan W.J., Balster R.L., Razdan R.K., Martin B.R. Evaluation of cannabimimetic discriminative stimulus effects of anandamide and methylated fluoroanandamide in rhesus monkeys. Pharmacol. Biochem. Behav. 58:1997;1139-1143.
170. Willoughby K.A., Moore S.F., Martin B.R., Ellis E.F. The biodisposition and metabolism of anandamide in mice. J. Pharmacol. Exp. Ther. 282:1997;243-247.
171. Wise M.L., Soderstrom K., Murray T.F., Gerwick W.H. Synthesis and cannabinoid receptor binding activity of conjugated triene anandamide, a novel eicosanoid. Experientia. 52:1996;88-92.
172. Yu M., Ives D., Ramesha C.S. Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. J. Biol. Chem. 272:1997;21181-21186.
173. Zygmunt P.M., Hogestatt E.D., Waldeck K., Edwards G., Kirkup A.J., Weston A.H. Studies on the effects of anandamide in rat hepatic artery. Br. J. Pharmacol. 122:1997;1679-1686.